TY - JOUR
T1 - Photodynamic monotherapy or combination treatment with intravitreal triamcinolone acetonide, bevacizumab or ranibizumab for choroidal neovascularization associated with pathological myopia
AU - Rishi, Pukhraj
AU - Rishi, Ekta
AU - Venkataraman, Anusha
AU - Gopal, Lingam
AU - Sharma, Tarun
AU - Bhende, Muna
AU - Ratra, Dhanashree
AU - Sen, Pratik
AU - Sen, Parveen
PY - 2011/5
Y1 - 2011/5
N2 - This retrospective, interventional case series analyses treatment outcomes in eyes with choroidal neovascularization (CNV) secondary to pathological myopia, managed with photodynamic therapy, (PDT), (Group 1, N = 11), PDT and intravitreal triamcinolone acetonide (4 mg/0.1ml) (Group 2, N = 3), PDT and intravitreal anti-vascular endothelial growth factor (anti-VEGF) bevacizumab 1.25 mg/0.05 ml, ranibizumab 0.5 mg/0.05 ml and reduced-fluence PDT and intravitreal ranibizumab 0.5 mg/0.05 ml (Group 3, N=12). All the patients underwent PDT. Intravitreal injections were repeated as required. SPSS 14 software was used to evaluate the data. Wilcoxon signed ranks test was used to evaluate pre- and post-treatment vision. The Kruskal-Wallis test was used for comparison between the groups. All the groups were statistically comparable. All the eyes showed complete regression of CNV, with a minimum follow-up of six months. All groups had visual improvement; significantly in Group 3 ( p = 0.003). Combination PDT with anti-VEGF agents appeared to be efficacious in eyes with myopic CNV. However, a larger study with a longer follow-up is required to validate these results.
AB - This retrospective, interventional case series analyses treatment outcomes in eyes with choroidal neovascularization (CNV) secondary to pathological myopia, managed with photodynamic therapy, (PDT), (Group 1, N = 11), PDT and intravitreal triamcinolone acetonide (4 mg/0.1ml) (Group 2, N = 3), PDT and intravitreal anti-vascular endothelial growth factor (anti-VEGF) bevacizumab 1.25 mg/0.05 ml, ranibizumab 0.5 mg/0.05 ml and reduced-fluence PDT and intravitreal ranibizumab 0.5 mg/0.05 ml (Group 3, N=12). All the patients underwent PDT. Intravitreal injections were repeated as required. SPSS 14 software was used to evaluate the data. Wilcoxon signed ranks test was used to evaluate pre- and post-treatment vision. The Kruskal-Wallis test was used for comparison between the groups. All the groups were statistically comparable. All the eyes showed complete regression of CNV, with a minimum follow-up of six months. All groups had visual improvement; significantly in Group 3 ( p = 0.003). Combination PDT with anti-VEGF agents appeared to be efficacious in eyes with myopic CNV. However, a larger study with a longer follow-up is required to validate these results.
KW - Bevacizumab
KW - choroidal neovascularization
KW - intravitreal injection
KW - myopia
KW - photodynamic therapy
KW - ranibizumab
KW - triamcinolone acetonide
KW - vascular endothelial growth factor
UR - http://www.scopus.com/inward/record.url?scp=79957536797&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79957536797&partnerID=8YFLogxK
U2 - 10.4103/0301-4738.81049
DO - 10.4103/0301-4738.81049
M3 - Article
C2 - 21586852
AN - SCOPUS:79957536797
SN - 0301-4738
VL - 59
SP - 242
EP - 246
JO - Indian Journal of Ophthalmology
JF - Indian Journal of Ophthalmology
IS - 3
ER -